IN2014MN01488A - - Google Patents
Info
- Publication number
- IN2014MN01488A IN2014MN01488A IN1488MUN2014A IN2014MN01488A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A IN 1488MUN2014 A IN1488MUN2014 A IN 1488MUN2014A IN 2014MN01488 A IN2014MN01488 A IN 2014MN01488A
- Authority
- IN
- India
- Prior art keywords
- mixture
- subunits
- subunit
- mol
- relative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580016P | 2011-12-23 | 2011-12-23 | |
US201261639654P | 2012-04-27 | 2012-04-27 | |
PCT/US2012/071477 WO2013096901A1 (en) | 2011-12-23 | 2012-12-21 | Pharmaceutical formulations for fumagillin derivative-phf conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01488A true IN2014MN01488A (sr) | 2015-04-17 |
Family
ID=48669583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1488MUN2014 IN2014MN01488A (sr) | 2011-12-23 | 2012-12-21 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20130189218A1 (sr) |
EP (1) | EP2794582A1 (sr) |
JP (1) | JP2015503635A (sr) |
KR (1) | KR20140121827A (sr) |
CN (1) | CN104024236A (sr) |
IN (1) | IN2014MN01488A (sr) |
TW (1) | TW201332574A (sr) |
UY (1) | UY34542A (sr) |
WO (1) | WO2013096901A1 (sr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
US10011657B2 (en) | 2014-10-31 | 2018-07-03 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
RU2020123953A (ru) | 2014-12-09 | 2020-09-18 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их |
US20170182179A1 (en) | 2014-12-09 | 2017-06-29 | Abbvie Inc. | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors |
AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
ES2811351T3 (es) | 2016-05-17 | 2021-03-11 | Abbvie Biotherapeutics Inc | Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso |
CA3026434A1 (en) * | 2016-06-03 | 2017-12-07 | Novacyte, Inc. | Polymer linkers and their uses |
CN109563167A (zh) | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗b7-h3抗体和抗体药物偶联物 |
CN116173232A (zh) | 2016-06-08 | 2023-05-30 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
US20190153107A1 (en) | 2016-06-08 | 2019-05-23 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
AU2017279550A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
AU2017277914A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
CA3027181A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
US20200338209A1 (en) | 2016-06-08 | 2020-10-29 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
AU2017277517A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
MX2018015272A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
KR20210027409A (ko) * | 2018-07-03 | 2021-03-10 | 페넥 파마슈티컬스, 인크. | 무수 싸이오황산나트륨 및 이의 제형 |
US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
BR112022002067A2 (pt) | 2019-08-08 | 2022-06-14 | Regeneron Pharma | Formatos de molécula de ligação ao antígeno |
KR20220093363A (ko) | 2019-11-05 | 2022-07-05 | 리제너론 파아마슈티컬스, 인크. | N-말단 scFv 다중특이적 결합 분자 |
CA3164037A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
JP2023520773A (ja) | 2020-03-27 | 2023-05-19 | ノバルティス アーゲー | 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療 |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
WO2022187591A1 (en) | 2021-03-05 | 2022-09-09 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
AU2022324456A1 (en) | 2021-08-05 | 2024-02-15 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
TW202325733A (zh) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | 抗醣化-lamp1抗體及其用途 |
CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
MX2010005857A (es) * | 2007-11-28 | 2010-11-22 | Mersana Therapeutics Inc | Conjugados de analogos de fumagillina biodegradables biocompatibles. |
KR20120057588A (ko) * | 2009-05-28 | 2012-06-05 | 메르사나 테라퓨틱스, 인코포레이티드 | 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체 |
-
2012
- 2012-12-21 KR KR1020147020754A patent/KR20140121827A/ko not_active Application Discontinuation
- 2012-12-21 JP JP2014548983A patent/JP2015503635A/ja active Pending
- 2012-12-21 IN IN1488MUN2014 patent/IN2014MN01488A/en unknown
- 2012-12-21 WO PCT/US2012/071477 patent/WO2013096901A1/en active Application Filing
- 2012-12-21 UY UY0001034542A patent/UY34542A/es not_active Application Discontinuation
- 2012-12-21 US US13/725,900 patent/US20130189218A1/en not_active Abandoned
- 2012-12-21 CN CN201280063450.4A patent/CN104024236A/zh active Pending
- 2012-12-21 TW TW101149115A patent/TW201332574A/zh unknown
- 2012-12-21 EP EP12858970.2A patent/EP2794582A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2013096901A1 (en) | 2013-06-27 |
JP2015503635A (ja) | 2015-02-02 |
EP2794582A1 (en) | 2014-10-29 |
UY34542A (es) | 2013-07-31 |
WO2013096901A8 (en) | 2014-08-07 |
US20130189218A1 (en) | 2013-07-25 |
KR20140121827A (ko) | 2014-10-16 |
TW201332574A (zh) | 2013-08-16 |
CN104024236A (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01488A (sr) | ||
EA201390600A1 (ru) | Терапевтические наночастицы с сополимерами с большим молекулярным весом | |
MX2018008061A (es) | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. | |
CY1120557T1 (el) | Μορια δεσμευσης anti-pseudomonas psl και χρησεις αυτων | |
MX347644B (es) | Macromoleculas estrella para el cuidado personal y del hogar. | |
MX2010009154A (es) | Moleculas conjugadas del factor viii. | |
WO2012135025A3 (en) | Conjugated lipomers and uses thereof | |
IN2014DN00101A (sr) | ||
GB201008902D0 (en) | Membrane enhanced polymer sythesis | |
EA201200617A1 (ru) | Полимеры на основе циклодекстрина для доставки лекарственных средств | |
MX2013007537A (es) | Formulacion farmaceutica que comprende una droga biofarmaceutica. | |
EP2555741A4 (en) | SPRAYABLE COMPOSITION COMPRISING A POLYMER FILLED WITH HIGH MOLECULAR WEIGHT | |
MX2012000575A (es) | Conjugados de epsilon-polilisina y uso de los mismos. | |
BR112013028365A2 (pt) | "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer". | |
UA101497C2 (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
ZA200707973B (en) | Low amounts of high molecular weight polymer for enhancing viscosity of aqueous/aqueous biphasic liquids | |
MX340118B (es) | Composiciones para el cuidado del cabello. | |
IN2014CN03735A (sr) | ||
BR112014004644A2 (pt) | polímeros funcionalizados com lactonas ou tiolactonas contendo um grupo amino protegido | |
EA201270186A1 (ru) | Фармацевтические композиции, содержащие модифицированные фуканы, для использования при лечении фиброзных спаек и других нарушений | |
WO2013186632A3 (en) | Conjugates of biologically active molecules to functionalized polymers | |
WO2013013753A3 (en) | Polymers and oligomers with functionalized side groups | |
MX2012006265A (es) | Formulaciones disacaridas hipersulfatadas. | |
WO2011130716A3 (en) | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers | |
BR112014016177A2 (pt) | composição de cloreto de polivinila, tubo, calha ou tanque, uso de uma composição de pvc e uso de tubo, calha ou tanque |